P374: Therapeutic drug monitoring can guide the intravenous-to-subcutaneous switch of infliximab and vedolizumab: a pharmacokinetic simulation studyECCO’23 CopenhagenYear: 2023
Authors: Wang, Z.(1)*;Verstockt , B.(2,3);Sabino , J.(2,3);Ferrante , M.(2,3);Vermeire , S.(2,3);Dreesen, E.(1);
(1)KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium;(2)KU Leuven, Department of Chronic Diseases and Metabolism, Leuven, Belgium;(3)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;
P375: Izencitinib induction treatment in patients with moderately-to-severely-active Crohn's Disease: A phase 2 double-blind, randomized, placebo-controlled studyECCO’23 CopenhagenYear: 2023
Authors: Schreiber, S.(1);Reinisch, W.(2);Nguyen, D.(3);Guerin, T.(4);Kierkus, J.(5);Rozpondek, P.(6);Bourdet, D.(7);Abhyankar, B.(8)*;Peyrin-Biroulet, L.(9);
(1)University Hospital Schleswig-Holstein- Kiel University- Kiel, Department of Internal Medicine I, Kiel, Germany;(2)Medical University of Vienna, Department Internal Medicine III, Vienna, Austria;(3)Former employee of Theravance Biopharma Inc, Research & Development, South San Francisco, United States;(4)Theravance Biopharma Ireland Ltd, Research & Development, Dublin, Ireland;(5)The Children's Memorial Health Institute- Warsaw- Poland, Department of Gastroenterology, Warsaw, Poland;(6)Krakow Medical Center, Krakow Medical Center, Krakow, Poland;(7)Theravance Biopharma Inc., Research and Development, South San Francisco, United States;(8)Former Employee- Theravance Biopharma Ireland Ltd, Clinical Development, Dublin, Ireland;(9)Nancy University Hospital- University of Lorraine- Vandoeuvre-lès-Nancy- France., Department of Gastroenterology, Vandoeuvre-lès-Nancy, France;
P376: Efficacy of ozanimod in vedolizumab-exposed patients with ulcerative colitis: a phase 3 True North post hoc analysisECCO’23 CopenhagenYear: 2023
Authors: Sands, B.E.(1)*;Jain, A.(2);Ahmad, H.A.(2);Osterman, M.(2);Memaj, A.(2);Canavan, J.B.(2);Axelrad, J.E.(3);
(1)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(2)Bristol Myers Squibb, Clinical Research, Princeton, United States;(3)NYU Grossman School of Medicine, Medicine, New York, United States;
P377: Changes over time in the Lémann Index and the Inflammatory Bowel Disease-Disability Index in patients with Crohn's diseaseECCO’23 CopenhagenYear: 2023
Authors: Wils, P.(1)*;Cartier, L.(2);Azahaf, M.(3);Hambli, S.(1);Branche, J.(1);Gérard, R.(1);Desreumaux, P.(1);Louvet, A.(1);Nachury, M.(1);
(1)Lille University Hospital, Gastroenterology Department, Lille, France;(2)Douai Hospital, Gastroenterology Department, Douai, France;(3)GHICL, Radiology Department, Lille, France;
P378: Pharmacokinetics of Vedolizumab and Ustekinumab in pregnant women with Inflammatory Bowel Disease and their infants exposed in-uteroECCO’23 CopenhagenYear: 2023
Authors: Prentice, R.(1)*;Flanagan, E.(2);Wright, E.K.(2);Gibson, P.R.(3);Rosella, S.(3);Rosella, O.(3);Goldberg, R.(1);Prideaux, L.(4);Kiburg, K.(5);Ross, A.L.(2);Burns, M.(1);Bell, S.J.(4);
(1)Monash Health, Gastroenterology, Melbourne, Australia;(2)St Vincent's Hospital Melbourne, Gastroenterology, Melbourne, Australia;(3)Monash University, Department of Medicine, Melbourne, Australia;(4)Monash Health, Gastroenterology, Clayton, Australia;(5)University of Melbourne, Department of Medicine, Melbourne, Australia;Pregnancy in Crohn's and Colitis: Observations Levels and Outcomes Extension (PICCOLO-X) Study Group
P379: Effect of upadacitinib on inflammatory markers and clinical outcomes in patients with Crohn's disease in the phase 3, U-EXCEL, U-EXCEED, and U-ENDURE studiesECCO’23 CopenhagenYear: 2023
Authors: Vermeire, S.(1)*;Danese, S.(2,3);Cohen, B.L.(4);Magro, F.(5);Chen, Y.(6);Ha, C.(7);Dubcenco, E.(8);Lacerda, A.P.(8);Marced, E.(8);Oomen, J.(8);Garrison, A.(8);Peyrin-Biroulet, L.(9);
(1)University Hospitals of Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(2)IRCCS San Raffaele Hospital, Department of Gastroenterology and Endoscopy, Milan, Italy;(3)Vita-Salute San Raffaele University, Gastroenterology, Milan, Italy;(4)Digestive Disease and Surgery Institute- Cleveland Clinic, Department of Gastroenterology- Hepatology- & Nutrition, Cleveland, United States;(5)University of Porto, Department of Biomedicine- Unit of Pharmacology and Therapeutics, Porto, Portugal;(6)The Second Affiliated Hospital of Zhejiang University School of Medicine, Department of Gastroenterology, Hangzhou, China;(7)Mayo Clinic, Division of Gastroenterology and Hepatology, Scottsdale, United States;(8)AbbVie Inc., Research and Development, North Chicago, United States;(9)Nancy University Hospital- University of Lorraine, Department of Gastroenterology and Inserum NGERE, Vandoeuvre-lès-Nancy, France;
P380: Changes in faecal microbiome and metabolome are more pronounced in Crohn's disease patients who adhered to the CD-TREAT diet and responded by calprotectin.ECCO’23 CopenhagenYear: 2023
Authors: Svolos, V.(1)*;Hansen, R.(2);Russell, R.K.(3);Gaya, D.R.(4);John Paul, S.(5);Macdonald, J.(5);Wilson, D.(3);Henderson, P.(3);Din, S.(6);Ho, G.T.(6);Quince, C.(7);Ijaz, U.Z.(8);Milling, S.(9);Nichols, B.(1);Papadopoulou, R.(1);McKirdy, S.(1);Gervais, L.(2);Shields, S.(5);Gerasimidis, K.(1);
(1)University of Glasgow, Human Nutrition- School of Medicine- Dentistry & Nursing- College of Medical- Veterinary and Life Sciences, Glasgow, United Kingdom;(2)Royal Hospital for Children, Department of Paediatric Gastroenterology- Hepatology and Nutrition, Glasgow, United Kingdom;(3)Royal Hospital for Children and Young People, Department of Paediatric Gastroenterology, Edinburgh, United Kingdom;(4)Glasgow Royal Infirmary, Department of Gastroenterology, Glasgow, United Kingdom;(5)Queen Elizabeth University Hospital, Department of Gastroenterology, Glasgow, United Kingdom;(6)Western General Hospital, Edinburgh IBD Unit- Department of Gastroenterology, Edinburgh, United Kingdom;(7)Norwich Research Park, Earlham Institute, Norwich, United Kingdom;(8)University of Glasgow-, School of Engineering, Glasgow, United Kingdom;(9)University of Glasgow, Institute of Infection- Immunity and Inflammation- College of Medical- Veterinary and Life Sciences, Glasgow, United Kingdom;
P382: Serum Ustekinumab Concentrations are Associated with Improved Outcomes with the Magnetic Resonance Index of Activity for Crohn's DiseaseECCO’23 CopenhagenYear: 2023
Authors: Chen, K.(1,2)*;Chen, J.(3);Smith, E.(1,2);Mathani, P.(1,2);Longman, R.(1,2);Lukin, D.(1,2);Scherl, E.(1,2);Battat, R.(1,2);
(1)Weill Cornell Medicine, Division of Gastroenterology- Department of Medicine, New York, United States;(2)Weill Cornell Medicine, Jill Roberts Center for Inflammatory Bowel Disease, New York, United States;(3)Weill Cornell Medicine, Department of Radiology, New York, United States;
P383: Real-life experience of the efficacy, safety and pharmacokinetic data of switching from intravenous to subcutaneous infliximab in inactive inflammatory bowel disease patients. Results from the ENEIDA registry.ECCO’23 CopenhagenYear: 2023
Authors: Iborra Colomino, M.I.(1)*;Garrido Marín, A.(1);Caballol Oliva, B.(2);Huguet Malavés, J.M.(3);Arias García, L.(4);Mesonero Gismero, F.(5);Fernández Prada, S.J.(6);Boscá Watts, M.M.(7);Ponferrada Díaz, Á.(8);Calvet Calvo, X.(9);Gutiérrez Casbas, A.(10); Ordás Jiménez, I.(2);Ruiz Sanchez, L.(3);Sicilia Aladren, B.(4);Garcia de la Filia, I.(5);Domènech Morral, E.(11);Nos Mateu, P.(1);
(1)Hospital Universitario y Politécnico la Fe de Valencia, Gastroenterology, Valencia, Spain;(2)Hospital Clínic de Barcelona, Gastroenterology, Barcelona, Spain;(3)Consorcio Hospital General Universitario de Valencia, Gastroenterology, Valencia, Spain;(4)Hospital Universitario de Burgos, Gastroenterology, Burgos, Spain;(5)Hospital Universitario Ramón y Cajal, Gastroenterology, Madrid, Spain;(6)Hospital Universitario Río Hortega de Valladolid, Gastroenterology, Valladolid, Spain;(7)Hospital Clínico Universitario de Valencia, Gastroenterology, Valencia, Spain;(8)Hospital Universitario Infanta Leonor Madrid, Gastroenterology, Madrid, Spain;(9)Hospital Universitari Parc Taulí, Gastroenterology, Sabadell, Spain;(10)Hospital General Universitario de Alicante Doctor Balmis, Gastroenterology, Alicante, Spain;(11)Hospital Universitari Germans Trias i Pujol, Gastroenterology, Badalona, Spain;
P384: A higher red blood cell methotrexate polyglutamate 3 concentration is associated with methotrexate drug-survival in patients with Crohn's Disease: first results of a prospective cohortECCO’23 CopenhagenYear: 2023
Authors: Van De Meeberg, M.(1)*;Fidder, H.(2);Sundaresan, J.(3);Struys, E.(3);Oldenburg, B.(2);Mares, W.(4);Mahmmod, N.(5);van Asseldonk, D.(6);Lutgens, M.(7);Kuyvenhoven, J.(8);Rietdijk, S.(9);Nissen, L.(10);Koehestanie, P.(11);de Jonge, R.(3);Bulatović Ćalasan, M.(12);Bouma, G.(13);
(1)Amsterdam UMC, Department of Gastroenterology, Amsterdam, The Netherlands;(2)UMC Utrecht, Department of Gastroenterology and Hepatology, Utrecht, The Netherlands;(3)Amsterdam UMC, Department of Clinical Chemistry, Amsterdam, The Netherlands;(4)Gelderse Vallei Hospital, Department of Gastroenterology and Hepatology, Ede, The Netherlands;(5)Sint Antonius Hospital, Department of Gastroenterology and Hepatology, Nieuwegein, The Netherlands;(6)Noordwest Hospital, Department of Gastroenterology and Hepatology, Alkmaar, The Netherlands;(7)Elizabeth - Tweesteden Hospital, Department of Gastroenterology and Hepatology, Tilburg, The Netherlands;(8)Spaarne gasthuis, Department of Gastroenterology and Hepatology, Hoofddorp, The Netherlands;(9)OLVG, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(10)Jeroen Bosch Hospital, Department of Gastroenterology and Hepatology, 's Hertogenbosch, The Netherlands;(11)Bravis Hospital, Department of Gastroenterology and Hepatology, Roosendaal, The Netherlands;(12)UMC Utrecht, Department of Rheumatology and Clinical Immunology, Utrecht, The Netherlands;(13)Amsterdam UMC, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;Dutch Initiative on Crohn and Colitis (ICC)
P385: Risk-benefit assessment of IBD drugs: a physicians and patients surveyECCO’23 CopenhagenYear: 2023
Authors: D'Amico, F.(1)*;Caron, B.(2);Vieujean, S.(3);Peyrin-Biroulet, L.(2);Danese, S.(1);
(1)IRCCS San Raffaele Hospital, Gastroenterology and Endoscopy, Milan, Italy;(2)University of Lorraine, Inserm- NGERE, F-54000 Nancy, France;(3)University Hospital CHU of Liège, Hepato-Gastroenterology and Digestive Oncology, Liège, Belgium;
P386: Clinical presentation, management, and evolution of lymphomas in patients with Inflammatory Bowel Disease: an ENEIDA registry study.ECCO’23 CopenhagenYear: 2023
Authors: Guerra Marina, I.(1)*;Bujanda, L.(2,3);Mañosa, M.(3,4);Pérez-Martínez, I.(5);Casanova, M.J.(3,6);de la Peña, L.(7);de Benito, M.(8);Rivero, M.(9);Varela, P.(10);Bernal, L.(3,11);Franco, A.C.(12);Ber, Y.(13);Piqueras, M.(14);Tardillo, C.(15);Ponferrada, Á.(16);Olivares, S.(17);Lucendo, A.J.(18);Gilabert, P.(19);Sierra Ausín, M.(20);Bellart, M.(1);Herrarte, A.(2);Calafat, M.(3,4);de Francisco, R.(5);P. Gisbert, J.(3,6);Guardiola, J.(7);Domènech, E.(3,4);Bermejo, F.(1);
(1)Hospital Universitario de Fuenlabrada, Gastroenterology, Fuenlabrada, Spain;(2)Hospital Donostia/Instituto Biodonostia- Universidad del País Vasco UPV/EHU, Gastroenterology, Donostia-San Sebastián, Spain;(3)Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gastroenterology, Spain, Spain;(4)Hospital Universitari Germans Trias i Pujol, Gastroenterology, Badalona, Spain;(5)Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias ISPA, Gastroenterology, Oviedo, Spain;(6)Hospital Universitario de La Princesa- IIS-Princesa- Universidad Autónoma de Madrid UAM, Gastroenterology, Madrid, Spain;(7)Hospital Universitari de Bellvitge- Institut d'Investigació Biomèdica de Bellvitge IDIBELL- Universitat de Barcelona, Gastroenterology, l´Hospitalet de Llobregat, Spain;(8)Hospital Universitario Río Hortega, Gastroenterology, Valladolid, Spain;(9)Hospital Universitario Marqués de Valdecilla and IDIVAL, Gastroenterology, Santander, Spain;(10)Hospital Universitario de Cabueñes, Gastroenterology, Gijón, Spain;(11)Hospital General Universitario Dr Balmis de Alicante, Gastroenterology, Alicante, Spain;(12)Hospital Universitario de Fuenlabrada, Onco-Hematology, Fuenlabrada, Spain;(13)Hospital General San Jorge, Gastroenterology, Huesca, Spain;(14)Consorci Sanitari Terrassa, Gastroenterology, Terrassa, Spain;(15)Hospital Universitario Nuestra Señora de la Candelaria, Gastroenterology, Tenerife, Spain;(16)Hospital Universitario Infanta Leonor, Gastroenterology, Madrid, Spain;(17)Hospital 12 de Octubre, Gastroenterology, Madrid, Spain;(18)Hospital General de Tomelloso, Gastroenterology, Ciudad Real, Spain;(19)Hospital de Viladecans, Gastroenterology, Barcelona, Spain;(20)Complejo Asistencial Universitario de León, Gastroenterology, León, Spain;On behalf of the ENEIDA project of GETECCU.
P387: Different rate of transmural remission between first and second line of biologic treatment in Crohn's diseaseECCO’23 CopenhagenYear: 2023
Authors: De Sire, R.(1)*;Rispo, A.(1);Caiazzo, A.(1);Testa, A.(1);Nardone, O.M.(1);Guarino, A.D.(1);Olmo, O.(1);Calabrese, G.(1);Fierro, G.(1);Toro, B.(1);Cantisani, N.M.(1);Ferrante, M.(1);La Mantia, A.(1);D'Alessandro, E.(1);Castiglione, F.(1);
(1)University Federico II of Naples, Department of Clinical Medicine and Surgery, Naples, Italy;
P388: Shear wave elastography predicts short-term response to induction therapy in patients with Crohn's diseaseECCO’23 CopenhagenYear: 2023
Authors: Sagami, S.(1,2)*;Morikubo, H.(1,2);Miyatani, Y.(1);Fukuda, T.(1,2);Asonuma, K.(1);Maeda, M.(1,2);Yoko, Y.(1,2);Karashima, R.(1,2);Hojo, A.(1,2);Nakano, M.(1,2);Hibi, T.(1);Kobayashi, T.(1,2,3);
(1)Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan;(2)Kitasato University Kitasato Institute Hospital, Department of Gastroenterology, Tokyo, Japan;(3)Kitasato University School of Medicine, Department of Gastroenterology, Kanagawa, Japan;
P389: Switching infliximab to subcutaneous from intravenous therapy (SWIMSUIT) – A prospective, real-world, single centre, phase IV interventional study.ECCO’23 CopenhagenYear: 2023
Authors: Rahmany, S.(1)*;Young, D.(1);Moyses, H.(2);Gonclaves, J.(3);Latter, S.(4);Cummings, F.(1,5);
(1)University Hospital Southampton NHS Foundation Trust, Gastroenterology, Southampton, United Kingdom;(2)University Hospital Southampton NHS Foundation Trust, NIHR Biomedical Research Centre, Southampton, United Kingdom;(3)University of Lisbon, iMed – Research Institute for Medicines- Department of Pharmacy, Lisbon, Portugal;(4)University of Southampton, School of Health Sciences, Southampton, United Kingdom;(5)University of Southampton, Faculty of Medicine, Southampton, United Kingdom;
P390: Ustekinumab modulates IL-12 and IL-23-related cell type-specific inflammatory transcriptional states in Ulcerative Colitis induction therapyECCO’23 CopenhagenYear: 2023
Authors: Richards, D.(1)*;Venkat, S.(1);Freeman, T.C.(1);Mcrae, B.(1);Hoops, T.(1);Marano, C.(1);Branigan, P.(1);
(1)Janssen Research & Development- LLC, Translational Sciences- Immunology, Spring House, United States;
P391: Relative association of bowel urgency clinically meaningful improvement or bowel urgency remission versus stool frequency remission and rectal bleeding remission with improvement in Inflammatory Bowel Disease Questionnaire scores in patients with moderately-to-severely active Ulcerative Colitis: An analysis from LUCENT-1 and LUCENT-2 phase 3 clinical trialsECCO’23 CopenhagenYear: 2023
Authors: Sands, B.E.(1)*;Feagan, B.(2,3);Gibble, T.H.(4);Keohane, A.(4);Eastman, W.(4);Traxler, K.(4);Schreiber, S.(5);Jairath, V.(6);Armuzzi, A.(7);
(1)Icahn School of Medicine- Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;(2)Alimentiv- Inc, Clinical research, London- Ontario, Canada;(3)Western University, Gastroenterology, London- Ontario, Canada;(4)Eli Lilly and Company, Immunology, Indianapolis, United States;(5)University Hospital Schleswig-Holstein- Kiel University-, Clinic for Internal Medicine I, Kiel, Germany;(6)University Hospital, Department of Medicine, London- Ontario, Canada;(7)Humanitas Research Hospital- Rozzano, Gastroenterology, Milan, Italy;
P392: Risk factors for postoperative recurrence after ileocolic resection for Crohn's Disease: long-term results from a population-based cohort.ECCO’23 CopenhagenYear: 2023
Authors: van Renterghem, A.(1)*;van der Holst, A.(1);van Kuijk, S.(2);Pierik, M.(3);Belgers, E.(4);Romberg-Camps, M.(5);Jeuring, S.(3);Demandt, D.(1);Stassen, L.(1);
(1)Maastricht University Medical Centre +, Surgery, Maastricht, The Netherlands;(2)Maastricht University Medical Centre +, Epidemiology, Maastricht, The Netherlands;(3)Maastricht University Medical Centre +, Gastroenterology, Maastricht, The Netherlands;(4)Zuyderland Medical Centre, Surgery, Heerlen, The Netherlands;(5)Zuyderland Medical Centre, Gastroenterology, Heerlen, The Netherlands;
